Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 425,778 |
|
|||||
| News | (1) | ||||||
| Day High | 25.155 | Low High |
|||||
| Day Low | 23.62 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Enliven Therapeutics Inc | ELVN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.59 | -2.41% | 23.90 | 15:30:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 24.85 | 23.62 | 25.155 | 23.90 | 24.49 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,016 | 425,778 | US$ 24.59 | US$ 10,470,865 | - | 9.80 - 26.00 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:02:10 | 2 | US$ 23.90 | USD |
Enliven Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 261.32M | 41.35M | - | 0 | -71.58M | -1.73 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Enliven Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ELVN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 18.29 | 25.155 | 18.29 | 23.51 | 410,493 | 5.61 | 30.67% |
| 1 Month | 24.015 | 26.00 | 15.96 | 20.89 | 559,109 | -0.115 | -0.48% |
| 3 Months | 17.30 | 26.00 | 10.9001 | 19.53 | 301,018 | 6.60 | 38.15% |
| 6 Months | 12.50 | 26.00 | 9.80 | 17.16 | 225,211 | 11.40 | 91.20% |
| 1 Year | 18.89 | 26.00 | 9.80 | 17.76 | 190,246 | 5.01 | 26.52% |
| 3 Years | 24.20 | 26.00 | 9.80 | 18.17 | 179,652 | -0.30 | -1.24% |
| 5 Years | 24.20 | 26.00 | 9.80 | 18.17 | 179,652 | -0.30 | -1.24% |
Enliven Therapeutics Description
| Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective, and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). |
